Pharmacokinetic/pharmacodynamic-based decision making in the development of MK-0888, a VEGFR-2/FLT-3 kinase inhibitorMarian Iwamoto, John A. Wagner, Evan Friedman et al.|Cancer Chemotherapy and Pharmacology|2014Cited by 0